RGS2 has been shown to suppress oncogenic signaling by inhibiting the phosphorylation of ERK and AKT (19, 33) This mechanism is particularly evident in colon tumors, where ERK and AKT phosphorylation are critical regulatory events driving malignant transformation and cancer cell behavior (34, 35). The gene discussed is AKT1; the disease is cancer.